Donald Trump’s new administration has the opportunity to address a critical but little-known aspect of our country’s health ...

A new coverage determination will prevent Medicare patients with certain cancers from accessing genetic testing, a move that advocates and testing companies say will severely limit early interventions ...

Shares of Guardant Health (NASDAQ:GH) have increased by 5.0% in premarket trading Tuesday following the company's announcement that its Guardant Reveal test for colon cancer has been granted expanded ...

On Tuesday, Guardant Health, Inc. (NASDAQ:GH) announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted ...

Skin substitute grafts made from cellular and tissue-based products have helped to revolutionize chronic wound care, but federal regulators are greatly reducing coverage for Medicare beneficiaries.

Abbott Park, Ill.-based Abbott Laboratories finally brought the story full circle with a successful national coverage determination that gives the device nationwide coverage for Medicare patients ...

(Nasdaq: GH), a leading precision oncology company, today announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX ...

Novitas, a Medicare Administrative Contractor, finalized a local coverage determination with the non-coverage decision for Castle’s DecisionDx-SCC test, listing the test among a number that it ...

The 119th Congress and the Trump Administration have before them significant challenges for long-term healthcare reforms. | To help prevent painful injuries and costly hospitalizations, and reduce ...